Invariantum

Veeva holds pharma's most valuable regulated data infrastructure, but AI could either monetise that moat or compress the headcount-based demand it runs on.

Biology is shifting toward data, AI, and simulation. The real value is in platforms and compute, while robotics speeds progress. Traditional biotech offers lower, less scalable returns.